On January 17, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that it will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO (Free ASCO Whitepaper) 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco (Press release, Guardant Health, JAN 17, 2024, https://www.businesswire.com/news/home/20240117367538/en/Guardant-Health-to-present-data-at-ASCO-GI-supporting-use-of-liquid-biopsy-to-predict-colon-cancer-recurrence [SID1234639302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guardant Reveal analyzes comprehensive molecular signals in the blood to detect and quantify minimal residual disease (MRD). The COSMOS study evaluated the use of the newest version of the test, built on the Guardant Infinity smart liquid biopsy platform, to identify MRD and predict disease recurrence in 130 patients with early-stage (II and III) colon cancer. Interim data to be shared at ASCO (Free ASCO Whitepaper) GI suggest the test is both highly specific (low false positives) and predictive for recurrence, without dependence on a tissue sample.

"Studies have established the presence of residual disease after surgery is associated with a higher probability of recurrence in early-stage colon cancer," said Craig Eagle, M.D., Guardant Health chief medical officer. "The interim COSMOS data are very promising and support the use of Guardant Reveal to predict disease recurrence and help inform adjuvant therapy decisions for patients with Stage II or III colon cancer."

Guardant and its research partners will also present multiple posters at the symposium highlighting the application of Guardant technology in blood-based screening and in identifying potentially targetable mutations in GI cancers, including predictive markers for treatment resistance.

Guardant Health 2024 ASCO (Free ASCO Whitepaper) GI Poster Presentations

Guardant Reveal

Multiomic Analysis for Minimal Residual Disease Detection: Addressing Challenges in Stage II-III Colon Cancer from COSMOS-CRC-01 (Abstract 180 | Poster Bd L8)
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer (ACT3) (Abstract 148 | Poster Bd J14)
Phase II results of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) Phase II/III Study (Oral Abstract Session; Abstract 5)
Guardant360

The genomic landscape of advanced colorectal adenocarcinoma patients with PIK3CA mutations using comprehensive cell free tumor DNA next generation sequencing (Abstract 181 | Poster Bd L9)
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer (Abstract 170 | Poster Bd K18)
GuardantINFORM

Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC) (Abstract 158 | Poster Bd K6)
Real-world testing and treatment patterns and outcomes following liquid biopsy in advanced cholangiocarcinoma (Abstract 455 | Poster Bd A20)
Assessment of circulating tumor DNA (ctDNA) burden and association with outcomes in metastatic gastric cancer (mGC) patients using real-world data (RWD) (Abstract 276 | Poster Bd C14)
Shield

Enhanced blood-based colorectal cancer screening with improved performance in detection of early stage disease (Abstract 68 | Poster Bd E11)
Circulating tumor DNA (ctDNA) positivity and its association with clinicopathological characteristics by novel blood-based test for colorectal cancer (CRC) screening from a multi-center large cohort: COSMOS-CRC-01 (Abstract 69 | Poster Bd E12)
Prospective study of a multi-modal blood-based test for colorectal cancer screening (Abstract 70 | Poster Bd E13)
The full abstracts are available on the official ASCO (Free ASCO Whitepaper) 2024 GI Cancers Symposium website.